137 related articles for article (PubMed ID: 19032220)
1. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
Zand MS
Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
[No Abstract] [Full Text] [Related]
2. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in immunologic glomerular diseases.
Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
[TBL] [Abstract][Full Text] [Related]
4. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab.
Lehnhardt A; Mengel M; Pape L; Ehrich JH; Offner G; Strehlau J
Am J Transplant; 2006 Apr; 6(4):847-51. PubMed ID: 16539643
[TBL] [Abstract][Full Text] [Related]
5. Single-dose rituximab as induction in renal transplantation.
van den Hoogen MW; Hilbrands LB
Transplantation; 2010 May; 89(10):1295; author reply 1295. PubMed ID: 20555227
[No Abstract] [Full Text] [Related]
6. Pharmacodynamics of rituximab in kidney allotransplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
Schiffer L; Schiffer M; Merkel S; Schwarz A; Mengel M; Jürgens C; Schroeder C; Zoerner AA; Püllmann K; Bröcker V; Becker JU; Dämmrich ME; Träder J; Grosshennig A; Biertz F; Haller H; Koch A; Gwinner W
Trials; 2012 Oct; 13():199. PubMed ID: 23101480
[TBL] [Abstract][Full Text] [Related]
8. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection.
Scheepstra C; Bemelman FJ; van der Loos C; Rowshani AT; van Donselaar-Van der Pant KA; Idu MM; ten Berge IJ; Florquin S
Transplantation; 2008 Sep; 86(6):772-8. PubMed ID: 18813100
[TBL] [Abstract][Full Text] [Related]
9. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
10. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
[TBL] [Abstract][Full Text] [Related]
11. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation.
Mitsuhata N; Fujita R; Ito S; Mannami M; Keimei K
Transplantation; 2005 Nov; 80(9):1355. PubMed ID: 16314808
[No Abstract] [Full Text] [Related]
12. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
13. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
[TBL] [Abstract][Full Text] [Related]
14. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
15. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for humoral rejection after kidney transplantation: an update.
Rostaing L; Guilbeau-Frugier C; Kamar N
Transplantation; 2009 Apr; 87(8):1261. PubMed ID: 19384176
[No Abstract] [Full Text] [Related]
17. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival.
Bagnasco SM; Tsai W; Rahman MH; Kraus ES; Barisoni L; Vega R; Racusen LC; Haas M; Mohammed BS; Zachary AA; Montgomery RA
Am J Transplant; 2007 Aug; 7(8):1968-73. PubMed ID: 17617861
[TBL] [Abstract][Full Text] [Related]
18. Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens.
Martins HL; Silva C; Martini D; Noronha IL
Transplant Proc; 2007 Mar; 39(2):432-4. PubMed ID: 17362749
[TBL] [Abstract][Full Text] [Related]
19. Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.
Kelishadi SS; Azimzadeh AM; Zhang T; Stoddard T; Welty E; Avon C; Higuchi M; Laaris A; Cheng XF; McMahon C; Pierson RN
J Clin Invest; 2010 Apr; 120(4):1275-84. PubMed ID: 20335656
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in renal transplantation.
Barnett AN; Hadjianastassiou VG; Mamode N
Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
